Amicus Therapeutics, Inc. (0HF9.L)
USD 7.4
(-5.87%)
USD 7.4
(-5.87%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 387.85 Million USD | -12.56% |
| 2022 | 443.56 Million USD | 2.51% |
| 2021 | 432.72 Million USD | -0.49% |
| 2020 | 434.85 Million USD | 114.18% |
| 2019 | 203.03 Million USD | -36.89% |
| 2018 | 321.74 Million USD | 95.98% |
| 2017 | 164.16 Million USD | 6.28% |
| 2016 | 154.46 Million USD | 271.3% |
| 2015 | 41.6 Million USD | 295.82% |
| 2014 | 10.51 Million USD | -25.85% |
| 2013 | 14.17 Million USD | 4640.47% |
| 2012 | 299 Thousand USD | 0.0% |
| 2011 | - USD | -100.0% |
| 2010 | 1.04 Million USD | -55.46% |
| 2009 | 2.34 Million USD | 639.43% |
| 2008 | 317 Thousand USD | -73.45% |
| 2007 | 1.19 Million USD | -47.08% |
| 2006 | 2.25 Million USD | 207.21% |
| 2005 | 734.37 Thousand USD | 0.0% |
| 2003 | - USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 388.93 Million USD | 0.14% |
| 2024 Q1 | 388.39 Million USD | 0.14% |
| 2023 Q1 | 444 Million USD | 0.1% |
| 2023 Q2 | 444.32 Million USD | 0.07% |
| 2023 Q3 | 446.52 Million USD | 0.49% |
| 2023 Q4 | 387.85 Million USD | -13.14% |
| 2023 FY | 387.85 Million USD | -12.56% |
| 2022 Q4 | 443.56 Million USD | 0.05% |
| 2022 Q2 | 443.49 Million USD | 0.69% |
| 2022 Q3 | 443.33 Million USD | -0.04% |
| 2022 Q1 | 440.45 Million USD | 1.79% |
| 2022 FY | 443.56 Million USD | 2.51% |
| 2021 Q3 | 432.21 Million USD | -0.56% |
| 2021 FY | 432.72 Million USD | -0.49% |
| 2021 Q2 | 434.63 Million USD | 0.1% |
| 2021 Q4 | 432.72 Million USD | 0.12% |
| 2021 Q1 | 434.22 Million USD | -0.15% |
| 2020 FY | 434.85 Million USD | 114.18% |
| 2020 Q1 | 202.25 Million USD | -0.38% |
| 2020 Q2 | 193.7 Million USD | -4.23% |
| 2020 Q3 | 433.21 Million USD | 123.65% |
| 2020 Q4 | 434.85 Million USD | 0.38% |
| 2019 Q3 | 198.94 Million USD | 7.35% |
| 2019 Q1 | 204.91 Million USD | -36.31% |
| 2019 FY | 203.03 Million USD | -36.89% |
| 2019 Q2 | 185.32 Million USD | -9.56% |
| 2019 Q4 | 203.03 Million USD | 2.06% |
| 2018 Q4 | 321.74 Million USD | 0.92% |
| 2018 Q3 | 318.8 Million USD | 88.15% |
| 2018 Q2 | 169.44 Million USD | 1.6% |
| 2018 Q1 | 166.76 Million USD | 1.58% |
| 2018 FY | 321.74 Million USD | 95.98% |
| 2017 Q1 | 156.85 Million USD | 1.55% |
| 2017 FY | 164.16 Million USD | 6.28% |
| 2017 Q4 | 164.16 Million USD | 1.57% |
| 2017 Q3 | 161.63 Million USD | 1.55% |
| 2017 Q2 | 159.17 Million USD | 1.47% |
| 2016 Q1 | 38.5 Million USD | -7.43% |
| 2016 Q3 | 66.02 Million USD | 1.12% |
| 2016 Q4 | 154.46 Million USD | 133.95% |
| 2016 FY | 154.46 Million USD | 271.3% |
| 2016 Q2 | 65.29 Million USD | 69.56% |
| 2015 Q1 | 9.2 Million USD | -12.39% |
| 2015 Q4 | 41.6 Million USD | -16.8% |
| 2015 Q3 | 50 Million USD | 0.0% |
| 2015 FY | 41.6 Million USD | 295.82% |
| 2015 Q2 | - USD | -100.0% |
| 2014 Q3 | 11.8 Million USD | -9.88% |
| 2014 Q4 | 10.51 Million USD | -11.0% |
| 2014 Q2 | 13.1 Million USD | -7.82% |
| 2014 FY | 10.51 Million USD | -25.85% |
| 2014 Q1 | 14.21 Million USD | 0.3% |
| 2013 Q3 | - USD | -100.0% |
| 2013 Q4 | 14.17 Million USD | 0.0% |
| 2013 Q1 | 199 Thousand USD | -33.44% |
| 2013 Q2 | 100 Thousand USD | -49.75% |
| 2013 FY | 14.17 Million USD | 4640.47% |
| 2012 Q3 | 398 Thousand USD | -20.08% |
| 2012 Q2 | 498 Thousand USD | -16.58% |
| 2012 FY | 299 Thousand USD | 0.0% |
| 2012 Q1 | 597 Thousand USD | 0.0% |
| 2012 Q4 | 299 Thousand USD | -24.87% |
| 2011 Q2 | 418 Thousand USD | -42.82% |
| 2011 FY | - USD | -100.0% |
| 2011 Q4 | - USD | -100.0% |
| 2011 Q3 | 104 Thousand USD | -75.12% |
| 2011 Q1 | 731 Thousand USD | -29.98% |
| 2010 Q4 | 1.04 Million USD | -23.07% |
| 2010 FY | 1.04 Million USD | -55.46% |
| 2010 Q2 | 1.67 Million USD | -16.79% |
| 2010 Q3 | 1.35 Million USD | -18.74% |
| 2010 Q1 | 2 Million USD | -14.38% |
| 2009 FY | 2.34 Million USD | 639.43% |
| 2009 Q4 | 2.34 Million USD | -13.06% |
| 2009 Q3 | 2.69 Million USD | 25.34% |
| 2009 Q2 | 2.15 Million USD | 864.57% |
| 2009 Q1 | 223 Thousand USD | -29.65% |
| 2008 Q3 | 483 Thousand USD | -30.5% |
| 2008 Q1 | 918 Thousand USD | -23.12% |
| 2008 Q4 | 317 Thousand USD | -34.37% |
| 2008 Q2 | 695 Thousand USD | -24.29% |
| 2008 FY | 317 Thousand USD | -73.45% |
| 2007 FY | 1.19 Million USD | -47.08% |
| 2007 Q3 | 1.57 Million USD | -19.46% |
| 2007 Q2 | 1.95 Million USD | 2.41% |
| 2007 Q1 | 1.9 Million USD | -15.47% |
| 2007 Q4 | 1.19 Million USD | -24.09% |
| 2006 FY | 2.25 Million USD | 207.21% |
| 2006 Q4 | 2.25 Million USD | 0.0% |
| 2005 FY | 734.37 Thousand USD | 0.0% |
| 2005 Q4 | 734.37 Thousand USD | 0.0% |
| 2003 FY | - USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -198.203% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -580.596% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -748.835% |
| bluebird bio, Inc. | 224.41 Million USD | -72.828% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -946.031% |
| Imunon, Inc. | 1.13 Million USD | -33943.745% |
| Editas Medicine, Inc. | 24.37 Million USD | -1491.408% |
| IQVIA Holdings Inc. | 12.95 Billion USD | 97.006% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | 80.367% |
| Myriad Genetics, Inc. | 130.9 Million USD | -196.301% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -50.158% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -1068.388% |
| Verastem, Inc. | 40.08 Million USD | -867.565% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | 95.178% |
| Waters Corporation | 2.3 Billion USD | 83.177% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 98.761% |
| Biogen Inc. | 7.18 Billion USD | 94.604% |
| Nektar Therapeutics | 112.62 Million USD | -244.38% |
| Perrigo Company plc | 3.63 Billion USD | 89.323% |
| Dynavax Technologies Corporation | 252.41 Million USD | -53.657% |
| Illumina, Inc. | 1.48 Billion USD | 73.952% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -11875.986% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -38685.8% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -123.224% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -1547.725% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | 34.604% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -1057.267% |
| Evolus, Inc. | 120.35 Million USD | -222.251% |
| Adicet Bio, Inc. | 17.7 Million USD | -2090.917% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -12517.372% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | 85.65% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | 22.668% |
| FibroGen, Inc. | 89.69 Million USD | -332.409% |
| Agilent Technologies, Inc. | 2.73 Billion USD | 85.819% |
| OPKO Health, Inc. | 222.03 Million USD | -74.684% |
| Homology Medicines, Inc. | 43.17 Million USD | -798.319% |
| Geron Corporation | 35.05 Million USD | -1006.553% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | 83.446% |
| Exelixis, Inc. | 189.94 Million USD | -104.196% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -41337.821% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -300.899% |
| Zoetis Inc. | 6.56 Billion USD | 94.091% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -117.812% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -8710.95% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | 46.48% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -1034.419% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | 72.303% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | 65.753% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | 74.13% |
| Blueprint Medicines Corporation | 610.96 Million USD | 36.517% |
| Insmed Incorporated | 1.19 Billion USD | 67.498% |
| TG Therapeutics, Inc. | 100.11 Million USD | -287.401% |
| Incyte Corporation | 29.16 Million USD | -1230.012% |
| Emergent BioSolutions Inc. | 446.5 Million USD | 13.134% |